A group of proteins called 4E-BPs involved in memory formation are key to unlocking the antidepressant effect of ketamine in the brain, according a new study by researchers from three Canadian universities. Published today in Nature, the discovery could lead to better and safer treatments for certain patients suffering from major depression, say the scientists at Université de Montréal, McGill University and Carleton University. Because more than 30% of patients are resistant to selective serotonin reuptake inhibitors (SSRI), the most commonly-prescribed antidepressants, finding an effective treatment for major depressive disorder is challenging. Ketamine was first approved in the U.S. in the 1970s for anesthesia and pain relief. Since then, researchers have been studying new uses for this drug; last year the Food & Drug Administration approved it for patients with major depression that are treatment-resistant. Unlike standard antidepressants, which can take several weeks to have an effect, ketamine works within hours. Until now, little was known about the molecular mechanism that triggers the antidepressant effect of ketamine on the brain. In their study, the Canadian researchers investigated the effect of ketamine on behaviour and neuronal activity in mice. Using genetic tools to remove proteins from specific brain cells, the team found that when 4E-BPs are absent in the brain, specifically in neurons, ketamine cannot produce its antidepressant effect. 4E-BPs act as a switch to turn on or off the process of protein synthesis – an essential component of memory formation. “This is yet another prime example of how basic research, in this case the control of protein synthesis, leads to major discoveries in understanding disease, and the hope of curing it,” said study co-author Nahum Sonenberg, a professor in the Department of Biochemistry at McGill. The researchers examined the role of 4E-BPs on ketamine’s effect in two major types of neurons: excitatory neurons, which make up most of the neurons in certain parts of the brain, and inhibitory neurons, which control excitatory neurons and have important effects on behaviour. “We were expecting that 4E-BPs would only be important in excitatory cells, but surprisingly, removing 4E-BPs from inhibitory cells was sufficient to block the effect of ketamine,” said co-author Jean-Claude Lacaille, a professor in the Department of Neurosciences at UdeM. Medicine is not one-size-fits-all The discovery and approval of ketamine for treatment-resistant patients was considered a major advance in modern psychiatry. Despite its promise, ketamine remains a less-than-perfect therapy, because it can be addictive. The researchers hope that their findings will pave the way for better and safer antidepressant therapies for patients with major depressive disorder. “Too many decisions continue to be made by a trial-and-error approach that can prolong the suffering of patients and affect their quality of life,” said co-author Argel Aguilar-Valles, a former research associate at McGill and now an assistant professor at Carleton. “Our discovery has the potential to bring us closer to find a safer alternative to ketamine, and ultimately to a personalized medicine approach, where medical treatments are tailored to the individual characteristics of each patient,” he said. The study also involved a clinician-researcher, Dr. Gabriella Gobbi, from the Department of Psychiatry at McGill, who works with individuals affected with depression and other psychiatric illnesses. As a next step, the researchers will examine whether males and females have different responses to ketamine. This could have important implications for treatment for people with depressive disorders, among which women are significantly overrepresented, they said. Source
